非酒精性脂肪性肝病动物模型研究进展*

doi:10.3969/j.issn.1672-5069.2021.05.039

Abstract

Abstract: Objective The incidence rate of nonalcoholic fatty liver disease (NAFLD) is increasing. It might progress to the end-stage liver disease. However, there is still no specific treatment for this entity. Therefore, the establishment of representative animal models reflecting disease characteristics has become especially important. Although there are many different disease models, there is still a lack of NAFLD model which could cover the whole spectrum of this entity in human. In this paper, we reviewed the current progress on NAFLD model, focusing on animal model, 2D cell model, 3D liver model and their advantages and disadvantages.

Key words: Nonalcoholic fatty liver disease, Cell model, Animal model, Tissue engineering liver

Zhang Yizhi, Zhang Xiaohui, Chen Yu. Models of nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2021, 24(5): 761-764.

References

[1]Marchisello S, Di Pino A, Scicali R, et al. Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: An overview. Int J Mol Sci, 2019, 20(8): 1948.
[2]Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 2018, 24(7): 908-922.
[3]Solinas P, Isola M, Lilliu M A, et al. Animal models are reliably mimicking human diseases? A morphological study that compares animal with human NAFLD. Microsc Res Tech, 2014, 77(10): 790-796.
[4]Trak-Smayra V, Paradis V, Massart J, et al. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol, 2011, 92(6): 413-421.
[5]Yang S Q, Lin H Z, Lane M D, et al. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A, 1997, 94(6): 2557-2562.
[6]Leclercq I A, Farrell G C, Schriemer R, et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol, 2002, 37(2): 206-213.
[7]Gupta A, Leslie N R. Controlling PTEN (phosphatase and tensin homolog) stability: A dominant role for lysine 66. J Biol Chem, 2016, 291(35): 18465-18473.
[8]Zhang X. NAFLDrelated-HCC: The relationship with metabolic disorders. Adv Exp Med Biol, 2018, 1061: 55-62.
[9]Stiles B, Wang Y, Stahl A, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A, 2004, 101(7): 2082-2087.
[10] Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest, 2004, 113(12): 1774-1783.
[11] Nakayama H, Otabe S, Ueno T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism, 2007, 56(4): 470-475.
[12] Eccleston H B, Andringa K K, Betancourt A M, et al. Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid Redox Signal, 2011, 15(2): 447-459.
[13] Asgharpour A, Cazanave S C, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol, 2016, 65(3): 579-588.
[14] Subramanian S, Goodspeed L, Wang S, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res, 2011, 52(9): 1626-1635.
[15] Savard C, Tartaglione E V, Kuver R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology, 2013, 57(1): 81-92.
[16] Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease /nonalcoholic steatohepatitis. World J Gastroenterol, 2012, 18(19): 2300-2308.
[17] Matsuzawa N, Takamura T, Kurita S, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology, 2007, 46(5): 1392-1403.
[18] Subramanian S, Goodspeed L, Wang S, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res, 2011, 52(9): 1626-1635.
[19] Kohli R, Kirby M, Xanthakos S A, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology, 2010, 52(3): 934-944.
[20] Zhang X, Han J, Man K, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol, 2016, 64(1): 160-170.
[21] Kirsch R, Clarkson V, Shephard E G, et al. Rodent nutritional model of non‐alcoholic steatohepatitis: Species, strain and sex difference studies. J Gastroenterol Hepatol, 2003, 18(11): 1272-1282.
[22] De Minicis S, Agostinelli L, Rychlicki C, et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One, 2014, 9(5): e97136.
[23] 张玉佩, 孔怡琳, 杨钦河, 等. Nrf2/ARE通路相关因子在脂肪变性HepG2细胞中的表达及其意义. 中国应用生理学杂志, 2016, 32(1): 13-17.
[24] Ozyra M, Johansson I, Nordling A, et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci Rep, 2018, 8(1): 14297.
[25] 张程亮, 贺雯茜, 徐艳娇, 等. 果糖诱导非酒精性脂肪性肝病小鼠动物模型的构建和评价. 肝脏, 2017, 22(8): 700-704.
[26] 贺雯茜, 杨金玉, 徐艳娇, 等. 果糖诱导肝脂肪变性细胞模型建立及评价. 肝脏, 2019, 24(6): 638-642.
[27] Wang Y, Nicolas C T, Chen H S, et al. Recent advances in decellularization and recellularization for tissue-engineered liver grafts. Cells Tissues Organs, 2017, 203(4): 203-214.
[28] Yamada M, Utoh R, Ohashi K, et al. Controlled formation of heterotypic hepatic micro-organoids in anisotropic hydrogel microfibers for long-term preservation of liver-specific functions. Biomaterials, 2012, 33(33): 8304-8315.
[29] Rennert K, Steinborn S, Groger M, et al. A microfluidically perfused three dimensional human liver model. Biomaterials, 2015, 71: 119-131.
[30] Li Q, Uygun B E, Geerts S, et al. Proteomic analysis of naturally-sourced biological scaffolds. Biomaterials, 2016, 75: 37-46.
[31] Uygun B E, Soto-Gutierrez A, Yagi H, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med, 2010, 16(7): 814-820.
[32] Wu Q, Liu J, Liu L, et al. Establishment of an ex vivo model of nonalcoholic fatty liver disease using a tissue-engineered liver. ACS Biomater Sci Engin, 2018, 4(8): 3016-3026.
[33] Fakhoury-Sayegh N, Trak-Smayra V, Khazzaka A, et al. Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract, 2015, 9(4): 350-357.
[34] Perfield J W, Ortinau L C, Pickering R T, et al. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease inleptin-deficient Ob/Ob mice. J Obes, 2013, 2013: 1-8.
[35] Schattenberg J M, Galle P R. Animal models of non-alcoholic steatohepatitis: Of mice and man. Dig Dis, 2010, 28(1): 247-254.

Models of nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ma Shangji, Zheng Yang, Chen Xufeng, et al. Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease [J]. Journal of Practical Hepatology, 2021, 24(5): 705-708.
[2]	Tian Anran, Xu Ruirui, Hu Pingping, et al. Establishment of a cell model for screening human EFTUD2 gene-targeting small molecule compounds [J]. Journal of Practical Hepatology, 2021, 24(4): 472-475.
[3]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[4]	Chen Xi, Wang Wei, Gao Jianwei, et al. Impact of antiviral therapy efficacy of entecavir in patients with chronic hepatitis B and concomitant nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 343-346.
[5]	Jia Qunling, Xu Zhibin, Han Shu. Implication of magnetic resonanceimaging-proton density fat fraction in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 359-362.
[6]	Liu Xiangji, Liu Zhenxian, Wang Xiaoyan. Incidence of gallstone disease in middle-aged and elderly patients with nonalcoholic fatty liver disease and its relation to metabolic risk factors [J]. Journal of Practical Hepatology, 2021, 24(3): 363-366.
[7]	Jin Ying, Zhou Weizhen, Feng Shibing, et al. Prevalence of nonalcoholic fatty liver diseases in patients with intracerebral hemorrhage [J]. Journal of Practical Hepatology, 2021, 24(3): 367-370.
[8]	Xu Leilei, Xu Guanying, Jiang Kai, et al. CT imaging feature in patients with non-alcoholic fatty liver diseases with different TCM syndrome [J]. Journal of Practical Hepatology, 2021, 24(2): 216-219.
[9]	Chen Guangyu, Wang Hong, Wang Yaoshen, et al. Blood hemoglobin levels for risk of individuals apt to have nonalcoholic fatty liver disease risk [J]. Journal of Practical Hepatology, 2021, 24(1): 39-42.
[10]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[11]	Liang Xiaoli,Kuang Jisun,Liu Qiuli,et al. Therapeutic efficacy of fenofibrate at base of calorie restriction diet in the treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes [J]. Journal of Practical Hepatology, 2021, 24(1): 51-54.
[12]	Zhao Xiaochun,Zhong Qing,Liu Shuhong,et al. Changes and clinical implication of serum uric acid levels in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(1): 55-58.
[13]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[14]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[15]	Li Pingying, Li Juan, Xie Shouzhen, et al. Clinical application of FibroTouchand abdominal color ultrasound and computed tomography in diagnosis of individuals with nonalcoholic fatty liver disease in plateau regions [J]. Journal of Practical Hepatology, 2020, 23(6): 817-820.